Search by Drug Name or NDC
NDC 70709-0065-30 TASCENSO ODT 0.5 mg/1 Details
TASCENSO ODT 0.5 mg/1
TASCENSO ODT is a ORAL TABLET, ORALLY DISINTEGRATING in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Cycle Pharmaceuticals Ltd. The primary component is FINGOLIMOD LAURYL SULFATE.
Product Information
| NDC | 70709-0065 |
|---|---|
| Product ID | 70709-065_1bbc20be-48e4-41e4-8657-7024d4f2172e |
| Associated GPIs | |
| GCN Sequence Number | 084181 |
| GCN Sequence Number Description | fingolimod lauryl sulfate TAB RAPDIS 0.5 MG ORAL |
| HIC3 | H0E |
| HIC3 Description | AGENTS TO TREAT MULTIPLE SCLEROSIS |
| GCN | 53376 |
| HICL Sequence Number | 048165 |
| HICL Sequence Number Description | FINGOLIMOD LAURYL SULFATE |
| Brand/Generic | Brand |
| Proprietary Name | TASCENSO ODT |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Fingolimod Lauryl Sulfate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, ORALLY DISINTEGRATING |
| Route | ORAL |
| Active Ingredient Strength | 0.5 |
| Active Ingredient Units | mg/1 |
| Substance Name | FINGOLIMOD LAURYL SULFATE |
| Labeler Name | Cycle Pharmaceuticals Ltd |
| Pharmaceutical Class | Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA214962 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 70709-0065-30 (70709006530)
| NDC Package Code | 70709-065-30 |
|---|---|
| Billing NDC | 70709006530 |
| Package | 3 BLISTER PACK in 1 CARTON (70709-065-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
| Marketing Start Date | 2023-02-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |